• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Omnicell’s Shift Toward Software and Services Require Action From Omnicell (OMCL) Investors?

    Simply Wall St·03/01/2026 06:17:28
    Listen to the news
    • Omnicell has recently accelerated its shift from hardware-focused sales toward software and services, including acquiring ANiGENT in October 2025 to broaden its drug diversion detection capabilities and recurring revenue base.
    • This pivot toward subscription-like revenue streams is prompting investors to reassess Omnicell less as a traditional equipment maker and more as a healthcare IT provider, with different expectations for growth, risk and valuation.
    • Next, we’ll examine how Omnicell’s push toward a software- and services-led model could reshape its existing investment narrative and risk profile.

    Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

    Omnicell Investment Narrative Recap

    To own Omnicell today, you need to believe its transition from hardware-heavy sales to a software and services model can eventually translate into healthier, more predictable earnings despite recent margin pressure. The ANiGENT acquisition fits this direction, enhancing Omnicell’s drug diversion detection tools and potentially reinforcing the key near term catalyst: growing recurring revenue. It does not, however, change the most immediate risk, which remains execution on this model shift while operating under cost and competitive pressures.

    The ANiGENT deal, announced in October 2025, is especially relevant here because it directly expands Omnicell’s footprint in medication intelligence and compliance software, areas more aligned with healthcare IT valuations than traditional equipment multiples. As this acquisition is integrated, investors will likely watch whether it contributes meaningfully to subscription like revenue, which could help offset tariff related cost pressures and macro driven delays in large automation purchases over the next few quarters.

    Yet, even as recurring revenue grows, investors should be aware that rising cybersecurity and compliance costs could...

    Read the full narrative on Omnicell (it's free!)

    Omnicell's narrative projects $1.3 billion revenue and $30.4 million earnings by 2028. This requires 3.0% yearly revenue growth and about a $7 million earnings increase from $23.1 million today.

    Uncover how Omnicell's forecasts yield a $57.43 fair value, a 40% upside to its current price.

    Exploring Other Perspectives

    OMCL 1-Year Stock Price Chart
    OMCL 1-Year Stock Price Chart

    Some of the most cautious analysts were only expecting about 2.5% annual revenue growth and earnings of roughly US$35.4 million by 2028, so compared with concerns about rising cybersecurity and regulatory costs they paint a much more restrained picture of what Omnicell’s shift toward software and services might deliver, and the latest ANiGENT news could ultimately challenge or reinforce that view in ways worth examining.

    Explore another fair value estimate on Omnicell - why the stock might be worth just $57.43!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    No Opportunity In Omnicell?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.